MedTrace Logo

Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia

NCT02313233 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2016-06-21

Study results available
· View outcomes & findings →

Summary

To evaluate the improvement in symptoms of Benign Prostatic Hyperplasia (BPH) according to the Prostate Symptom Score (IPSS) and Quality- of- Life (QoL) index after add- on therapy of Umooze twice daily administration for 56 days in patients with BPH.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

DIETARY_SUPPLEMENT

Umooze

Umooze is consisted of Astragalus radix extracts and soy extracts. Astragalus radix (AR) is the dried root of Astragalus membranaceus Bge. Var. mongholicus and is used as a tonic in the traditional Chinese medicine. According to the reports submitted by the National Cancer institute of American, people who eat soybean products can reduce the incidence rate for prostate cancer. The composition of Umooze is invented by Golden Biotechnology Corp. against prostatic hyperplasia.

DIETARY_SUPPLEMENT

Placebo

Placebo is consisted of cornstarch and is provided by by Golden Biotechnology Corp.

Sponsors & Collaborators

  • Golden Biotechnology Corporation

    lead INDUSTRY

Principal Investigators

  • Ching- Chia Li, M.D · Kaohsiung Municipal Ta-Tung Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02313233 on ClinicalTrials.gov